Wesseling P, Capper D (2018) WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol 44:139–150

Article  CAS  PubMed  Google Scholar 

Yao M, Li S, Wu X, Diao S, Zhang G, He H, Bian L, Lu Y (2018) Cellular origin of glioblastoma and its implication in precision therapy. Cell Mol Immunol 15:737

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R (2015) Glioma. Nat Rev Dis Primers 1:15017

Article  PubMed  Google Scholar 

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722

Article  CAS  PubMed  Google Scholar 

Sabahi M, Jabbari P, Haghighi MA, Soltani S, Soudi S, Rahmani F, Rezaei N (2020) Proposing a tandem AND gate CAR T cell targeting glioblastoma multiforme. Med Hypotheses 137:109559

Article  CAS  PubMed  Google Scholar 

Sattiraju A, Sai KKS, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz A (2017) IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget 8:42997

Article  PubMed  PubMed Central  Google Scholar 

Skog J (2006) Glioma-specific antigens for immune tumor therapy. Expert Rev Vaccines 5:793–802

Article  CAS  PubMed  Google Scholar 

Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, Garcia R, Demaria S, Newcomb EW (2005) Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 85:328–341

Article  CAS  PubMed  Google Scholar 

Fesnak AD, June CH, Levine BL (2016) Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 16:566

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sadelain M (2016) Chimeric antigen receptors: driving immunology towards synthetic biology. Curr Opin Immunol 41:68–76

Article  CAS  PubMed  PubMed Central  Google Scholar 

Locatelli F, Moretta F, Brescia L, Merli P (2014) Natural killer cells in the treatment of high-risk acute leukaemia. Semin Immunol. https://doi.org/10.1016/j.smim.2014.02.004

Article  PubMed  Google Scholar 

Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A (2011) Killer Ig–like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood J Am Soc Hematol 117:764–771

CAS  Google Scholar 

Yoon SR, Lee Y, Yang S, Ahn K, Lee J-H, Lee J-H, Kim D, Kang Y, Jeon M, Seol M (2010) Generation of donor natural killer cells from CD34 + progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant 45:1038–1046

Article  CAS  PubMed  Google Scholar 

Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui C-H, Leung W (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28:955

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5:1282–1295

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517–528

Article  CAS  PubMed  Google Scholar 

Campbell KS, Hasegawa J (2013) Natural killer cell biology: an update and future directions. J Allergy Clin Immunol 132:536–544. https://doi.org/10.1016/j.jaci.2013.07.006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malmberg K-J, Carlsten M, Björklund A, Sohlberg E, Bryceson YT, Ljunggren H-G (2017) Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol 31:20–29. https://doi.org/10.1016/j.smim.2017.08.002

Article  CAS  PubMed  Google Scholar 

Guillerey C, Huntington ND, Smyth MJ (2016) Targeting natural killer cells in cancer immunotherapy. Nat Immunol 17:1025–1036. https://doi.org/10.1038/ni.3518

Article  CAS  PubMed  Google Scholar 

Wu J, Lanier LL (2003) Natural killer cells and cancer. In: Vande Woude GF, Klein G (eds) Advances in cancer research. Academic Press, NY, pp 127–156

Google Scholar 

Santana MA, Esquivel-Guadarrama F (2006) Cell biology of T cell activation and differentiation. Int Rev Cytol 250:217–274

Article  CAS  PubMed  Google Scholar 

Agnihotri S, Burrell KE, Wolf A, Jalali S, Hawkins C, Rutka JT, Zadeh G (2013) Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp 61:25–41

Article  CAS  Google Scholar 

Rodriguez A, Brown C, Badie B (2017) Chimeric antigen receptor T-cell therapy for glioblastoma. Translational Res 187:93–102

Article  CAS  Google Scholar 

Maggs L, Cattaneo G, Dal AE, Moghaddam AS, Ferrone S (2021) CAR T cell-based immunotherapy for the treatment of glioblastoma. Front NeuroSci 15:535

Article  Google Scholar 

Sabahi M, Salehipour A, Bazl MSY, Rezaei N, Mansouri A, Borghei-Razavi H (2023) Local immunotherapy of glioblastoma: a comprehensive review of the concept. J Neuroimmunol 381:578146. https://doi.org/10.1016/j.jneuroim.2023.578146

Article  CAS  PubMed  Google Scholar 

Weinkove R, George P, Dasyam N, McLellan AD (2019) Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Translational Immunol 8:e1049. https://doi.org/10.1002/cti2.1049

Article  Google Scholar 

Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA (2016) CD28 Costimulation: from mechanism to Therapy. Immunity 44:973–988. https://doi.org/10.1016/j.immuni.2016.04.020

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu T, Zhang L, Joo D, Sun S-C (2017) NF-κB signaling in inflammation. Signal Transduct Target Therapy 2:17023. https://doi.org/10.1038/sigtrans.2017.23

Article  Google Scholar 

Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti G (2018) In vivo fate and activity of second- versus third-generation CD19-Specific CAR-T cells in B cell non-hodgkin’s lymphomas. Mol Therapy: J Am Soc Gene Therapy 26:2727–2737. https://doi.org/10.1016/j.ymthe.2018.09.009

Article  CAS  Google Scholar 

Chmielewski M, Hombach AA, Abken H (2014) Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 257:83–90. https://doi.org/10.1111/imr.12125

Article  CAS  PubMed  Google Scholar 

Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ (2017) Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep 7:10541. https://doi.org/10.1038/s41598-017-10940-8

Article  CAS  PubMed